Plain-English translation of NCT06852287 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new combination approach for people with advanced intrahepatic cholangiocarcinoma or gallbladder cancer that cannot be removed by surgery. The treatment combines three different medications: lenvatinib (a targeted therapy), toripalimab (an immunotherapy that helps your immune system fight cancer), and a chemotherapy regimen called GemOX that is delivered directly to the liver through a special catheter. The goal is to improve how well the treatment works while reducing side effects.
Current standard treatments for these cancers don't work well enough for many patients. By delivering chemotherapy directly to the liver through a catheter, doctors can give higher doses of medication exactly where the cancer is, while keeping overall drug doses lower. This trial tests whether combining this localized chemotherapy with two other medications might help more patients respond to treatment—and potentially make their cancer operable so surgery becomes possible.
You likely qualify if…
You likely don't qualify if…
You will receive three medications: one pill you take daily by mouth, an infusion through a vein every three weeks, and chemotherapy delivered through a special catheter placed in the artery that goes to your liver, also every three weeks. You will have regular clinic visits to check how you are responding to treatment, monitor for side effects, and have blood tests and imaging scans. The study will track your progress over time to see whether the cancer responds and whether surgery might become possible.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China